Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402365 | 1.00 | TSHR (0.62) | TSHRKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL3262084 | 0.87 | NPC1 (0.57) | TSHRKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL10173049 | 0.84 | NPC1 (0.51) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL19428476 | 0.83 | TSHR (0.56) | TSHRKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL24479513 | 0.81 | LPL (0.42) | TSHRKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL19057477 | 0.80 | SMN1; SMN2 (0.56) | KDM4ENPC1RAB9ANPSR1CYP1A2 | |
| SCHEMBL17544370 | 0.79 | MET (0.42) | TSHRKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL23606558 | 0.78 | SMN1; SMN2 (0.52) | KDM4ENPC1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL12182400 | 0.78 | KDM4E (0.79) | TSHRKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL402661 | 0.78 | LPL (0.44) | NPC1RAB9ACYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-107108534-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4006016-A2 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4006016-A2 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11059836-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059836-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200102328-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2020-04-02 | — | — | US | disclosed |
| US-10479802-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10479802-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| EP-3186233-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033445-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033445-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | TSHR 3168/4885KDM4E 4585/4885NPC1 163/4885 |
| US-10479802-B2 | Probes for imaging huntingtin protein | HTT, HYPK, FABP7 | TSHR 3104/4885KDM4E 4674/4885NPC1 112/4885 |
| US-11059836-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | TSHR 3168/4885KDM4E 4585/4885NPC1 163/4885 |
| US-20200102328-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | TSHR 3168/4885KDM4E 4585/4885NPC1 163/4885 |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | TSHR 3104/4885KDM4E 4674/4885NPC1 112/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | TSHR 3168/4885KDM4E 4585/4885NPC1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.